The China National Intellectual Property Administration (CNIPA) has accepted its first set of drug patent linkage complaints since the introduction of a new patent law in June 2021. The office confirmed the development in a statement released on October 29.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at email@example.com
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
China, complaints, patent, linkage, drug, companies, resolution, dispute